Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Redefining Accelerated Approval Criteria Would Expand Pathway’s Use, Panel Says

Executive Summary

Expanding the definition of “unmet medical need” and adopting a narrow, molecularly targeted approach to determining the existence of “available therapies” would enable use of the approval pathway in earlier treatment settings, a group of stakeholders tells a cancer research conference.

Advertisement

Related Content

FDA “Available Therapy” Determination Is A Moving Target, Industry Groups Say
FDA Envisions Flexible Approach To Expanded Use Of Accelerated Approval
FDA Eager For More Master Protocols in Oncology: Approach Means Lower Cost For Sponsors—and Less Control
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
“Breakthrough Therapy” Development Speed May Be Tempered By Manufacturing Hurdles
Genentech Resubmits T-DM1 To FDA, This Time With An Overall Survival Benefit
Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS054914

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel